Complement Pharma Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.41M
Complement Pharma General Information
Description
Developer of monoclonal antibody intended to treat neurodegenerative and immune-mediated disorders. The company's monoclonal antibody targets the complement pathway in order to treat immune-mediated disorders and accelerate nerve regeneration in neurological disorders and drug therapies for neurological disorders, thereby enabling patients to get an early-stage drug that treats and meets the unmet medical need.
Contact Information
Website
www.complementpharma.comCorporate Office
- Meibergdreef 9, K2 - 217
- 1105 Amsterdam
- Netherlands
Corporate Office
- Meibergdreef 9, K2 - 217
- 1105 Amsterdam
- Netherlands
Complement Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 11-Jun-2018 | $1.41M | Completed | Generating Revenue | ||
| 3. Early Stage VC | 01-Jan-2014 | Completed | Generating Revenue | |||
| 2. Debt - General | 12-Oct-2011 | $5M | $5.9M | Completed | Generating Revenue | |
| 1. Seed Round | 03-Dec-2010 | $900K | $900K | Completed | Generating Revenue |
Complement Pharma Patents
Complement Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016118007-A1 | Means and methods for counteracting complement-mediated hemolytic anemia | Inactive | 21-Jan-2015 | ||
| AU-2015365583-A1 | Antibodies that bind human c6 and uses thereof | Active | 19-Dec-2014 | ||
| AU-2015365583-B2 | Antibodies that bind human c6 and uses thereof | Active | 19-Dec-2014 | ||
| AU-2021240139-A1 | Antibodies that bind human c6 and uses thereof | Active | 19-Dec-2014 | ||
| AU-2021240139-B2 | Antibodies that bind human c6 and uses thereof | Active | 19-Dec-2014 | A61K39/395 |
Complement Pharma Signals
Complement Pharma Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amsterdam UMC Ventures Holding | Venture Capital | Minority | ||
| Life Sciences Fund Amsterdam | Venture Capital | Minority | ||
| Stichting ALS Nederland | Corporation | Minority | ||
| UvA Ventures Holding | Venture Capital | Minority | ||
| Ventac Partners | Venture Capital | Minority |
Complement Pharma FAQs
-
When was Complement Pharma founded?
Complement Pharma was founded in 2009.
-
Where is Complement Pharma headquartered?
Complement Pharma is headquartered in Amsterdam, Netherlands.
-
What is the size of Complement Pharma?
Complement Pharma has 1 total employees.
-
What industry is Complement Pharma in?
Complement Pharma’s primary industry is Drug Discovery.
-
Is Complement Pharma a private or public company?
Complement Pharma is a Private company.
-
What is the current valuation of Complement Pharma?
The current valuation of Complement Pharma is .
-
What is Complement Pharma’s current revenue?
The current revenue for Complement Pharma is .
-
How much funding has Complement Pharma raised over time?
Complement Pharma has raised $6.72M.
-
Who are Complement Pharma’s investors?
Amsterdam UMC Ventures Holding, Life Sciences Fund Amsterdam, Stichting ALS Nederland, UvA Ventures Holding, and Ventac Partners have invested in Complement Pharma.
-
When was Complement Pharma acquired?
Complement Pharma was acquired on 11-Jun-2018.
-
Who acquired Complement Pharma?
Complement Pharma was acquired by Alexion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process